Roche's Investigational Hepatitis C Polymerase Inhibitor, R1626, Demonstrated Significant End-of-Treatment Response In Phase IIa Study Roche's investigational therapy for chronic hepatitis C virus (HCV) infection, R1626, has shown a significant end-of-treatment response rate when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(R) (ribavirin). R1626 also shows a high barrier to the development of resistance.
Source: www.medicalnewstoday.comAnnual Treatment For Trachoma, As Recommended By WHO, May Be Unnecessary, If Treatment Coverage High Five year study indicates one or two treatments may be enough to eliminate infection One or two rounds of high coverage mass treatment with azithromycin, rather than the annual treatment recommended by the World
Health Organisation, may be enough to eliminate the eye disease trachoma in communities with moderate levels of infection.
Source: www.medicalnewstoday.comData Suggests Promising Overall Survival And Progression-free Survival With Vargatef? (BIBF 1120) Monotherapy treatment with the triple angiokinase inhibitor1 BIBF 1120 (planned tradename Vargatef ?) offers promising efficacy and is well tolerated in patients with advanced, relapsed non small cell lung cancer (NSCLC), according to results from a phase II study in patients with lung cancer2.
Source: www.medicalnewstoday.comWomen's Biological Clock Revealed: Hormone May Predict Age At Menopause Age at menopause may now be predicted more realistically according to a new study accepted for publication in the Journal of Clinical Endocrinology & Metabolism (JCEM). The study revealed that anti Mullerian hormone (AMH) levels are related to the onset of menopause and are able to specify a woman's reproductive age more accurately than chronological age alone.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 12:00 PM
